Abstract:8554 Background: Surgery is standard of care for patients with stage I non-small cell lung cancer (NSCLC). However, 5-year mortality can reach up to 30%. For patients with contraindication to surgery, treatment with stereotactic ablative radiotherapy (SABR) leads to adequate local tumor control, but has a high rate of regional and distant failure. SABR as neoadjuvant therapy for stage I NSCLC produced a pathologic complete response (pCR) rate of only 60% when surgery was performed after 10 weeks of treatment, demanding improvement in the management of both operable and inoperable early-stage NSCLC. Immune checkpoint inhibitors (ICI) are routinely used in stages III-IV NSCLC, with recent approvals in the peri-operative setting, and may be synergistic with radiotherapy. We hypothesized that neoadjuvant nivolumab plus SABR may improve pCR rate and provide insight to its changes in the tumor microenvironment. Methods: This is a phase 2, single arm, open label study evaluating neoadjuvant treatment for patients with NSCLC of up to 4 cm, with no lymph node involvement (AJCC 8th edition: up to cT2aN0), and adequate surgical conditions. Treatment consisted of nivolumab 360 mg every 3 weeks for 3 doses or unacceptable toxicity. SABR started on D1 of nivolumab, with a duration of 2 to 3 weeks, depending on the lesion size and location (3 x 18 Gy; or 5 x 10 Gy; or 8 x 7.5 Gy). Standard-of-care surgery was performed at 10 (+- 2) weeks after the last radiotherapy dose. The primary endpoint of the study is pCR rate at surgery. Tissue, blood, and stool samples were collected during treatment. Results: We included 25 patients. All but one were cared for in the Brazilian public system. Mean age was 68 years. Mean tumor size was 2.45 cm. Only 3 patients were never-smokers. Surgery was performed as scheduled in all but one patient. pCR rate was 80% (19/24) and MPR rate was 83% (20/24) of patients who underwent surgery. Twenty-nine treatment-emergent adverse events occurred in 13 patients (23 grade 1-2 events, two grade 3 and two grade 5 events, being only one grade 3 diarrhea related to experimental treatment). The single patient who was not operated died during study treatment from relapsed acute alcoholic hepatitis. The other grade 5 event was due to a respiratory infection, both unrelated to treatment. Two patients died from surgical complications 185 and 72 days after surgery, respectively (one with pulmonary artery lesion with subsequent clinical complications and other with thromboembolic events), deemed unrelated to experimental treatment. During follow-up, two additional patients died due to comorbidities, and none relapsed to date. Conclusions: In this trial with patients with significant comorbidities and smoking history from the public system in Brazil, we demonstrated a pCR rate of 80% with SABR + nivolumab. Further studies are warranted to evaluate this strategy versus surgery in operable patients with stage I disease. Clinical trial information: NCT04271384 .

Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial

A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)

A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up

Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment

Stereotactic prostate radiotherapy with or without androgen deprivation therapy, study protocol for a phase III, multi-institutional randomized-controlled trial

Stereotactic Ablative Radiotherapy for Oligoprogressive Cancers: Results of the Randomized Phase II STOP Trial

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer

A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocol

Preoperative stereotactic body radiotherapy combined with surgical treatment for renal cell carcinoma and inferior vena cava tumour thrombus: study protocol for a single-arm cohort trial

A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Stereotactic intensity modulated radiotherapy after radical prostatectomy (SCIMITAR): Two-year quality of life and toxicity outcomes of a multicenter phase II trial.

Two-fractionated stereotactic magnetic resonance-guided adaptive radiation therapy for patients with prostate cancer (SMART PRO trial): protocol for a confirmatory clinical trial

Phase III randomized trial of stereotactic ablative radiotherapy (SAbR) for oligometastatic advanced renal carcinoma (EA8211-SOAR).

Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial

Stereotactic Ablative Radiotherapy Boost to Bladder Tumor for Bladder Preservation in Patients with Muscle-Invasive Bladder Cancer

Clinical Outcomes of Prostate SBRT Using Non-adaptive MR-Guided Radiotherapy

Stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer: A phase 2 study.

MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial